Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Rev Argent Microbiol ; 2024 Jul 10.
Article in English | MEDLINE | ID: mdl-38991918

ABSTRACT

Understanding the proportion of SARS-CoV-2 patients with Mycoplasmapneumoniae coinfection is crucial for treating patients suffering from coronavirus disease (COVID-19), help to ensure responsible use of antibiotics and minimize the negative consequences of overuse. In addition, this knowledge could have an impact on empirical antibiotic management guidelines for patients with COVID-19. This systematic review aimed to identify the prevalence of M. pneumoniae in patients with coronavirus disease 2019 (COVID-19). A bibliographic search of studies published in Spanish or English was conducted using the PubMed search engine. Fourteen articles from different continents (America, Asia and Europe) were included, involving a total of 5855 patients in these studies. The mean age of COVID-19 patients with M. pneumoniae was 48 years old (range 1-107), most of whom were male. The detection of laboratory-confirmed M. pneumoniae infection varied between 0 and 33.3%. Most of patients referred fever, cough, and dyspnea, and received empirical antibiotic treatment. Bacterial coinfection was not associated with increased ICU admission and mortality. The prevalence of coinfection showed extremely dissimilar figures according to the population studied and diagnostic criteria. However, it is important to develop Latin American studies, given the heterogeneity observed in the studies conducted in different countries. Standardized definitions should be developed in order to be able to assess the impact of coinfections in patients with a diagnosis of COVID-19.

2.
Rev. argent. microbiol ; 54(3): 121-130, set. 2022. graf
Article in English | LILACS-Express | LILACS | ID: biblio-1407202

ABSTRACT

Abstract Bacterial co-pathogens are commonly identified in viral respiratory infections and are important causes of morbid-mortality. The prevalence of Chlamydia (C.) pneumoniae infection in patients infected with SARS-CoV-2 has not been sufficiently studied. The objective of the present review was to describe the prevalence of C. pneumoniae in patients with coronavirus disease 2019 (COVID-19). A search in MEDLINE and Google Scholar databases for English language literature published between January 2020 and August 2021 was performed. Studies evaluating patients with confirmed COVID-19 and reporting the simultaneous detection of C. pneumoniae were included. Eleven articles were included in the systematic review (5 case cross-sectional studies and 6 retrospective studies). A total of 18450 patients were included in the eleven studies. The detection of laboratory-confirmed C. pneumoniae infection varied between 1.78 and 71.4% of the total number of co-infections. The median age of patients ranged from 35 to 71 years old and 65% were male. Most of the studies reported one or more pre-existing comorbidities and the majority of the patients presented with fever, cough and dyspnea. Lymphopenia and eosinopenia were described in COVID-19 co-infected patients. The main chest CT scan showed a ground glass density shadow, consolidation and bilateral pneumonia. Most patients received empirical antibiotics. Bacterial co-infection was not associated with increased ICU admission and mortality. Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus 2-associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial co-infection. Prospective evidence generation to support the development of an antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic are urgently required.


Resumen Los patógenos bacterianos pueden detectarse en las infecciones respiratorias virales y son una causa importante de morbimortalidad. La prevalencia de Chlamydia pneumoniae en pacientes infectados con SARS-CoV-2 ha sido poco estudiada. El objetivo de la presente revisión fue describir la prevalencia de C. pneumoniae en pacientes con enfermedad por coronavirus 2019 (COVID-19). Para ello se realizó una búsqueda bibliográfica en Medline y Google Académico, entre enero de 2020 y agosto de 2021. De la revisión surgieron 11 artículos (cinco estudios de casos transversales y seis estudios retrospectivos), que incluyeron un total de 18.450 pacientes. La detección de C. pneumoniae varió entre el 1,78 y 71,4% del total de las coinfecciones. La media de edad de los pacientes osciló entre los 35 y 71 años y el 65% fueron hombres. En la mayoría de los estudios se informaron comorbilidades preexistentes y la mayor parte de los pacientes presentó fiebre, tos y disnea. Además, se describió linfopenia y eosinofilopenia en pacientes con COVID-19 coinfectados. La principal manifestación en la tomografía computarizada fue densidad de vidrio esmerilado, consolidación y neumonía bilateral. La mayoría de los pacientes recibió antibióticos de manera empírica. La coinfección bacteriana no se asoció con un aumento de ingresos en cuidados intensivos ni mortalidad. A pesar de la prescripción de antimicrobianos empíricos en pacientes con infecciones respiratorias asociadas a coronavirus existen pocos reportes de detección de coinfección bacteriana. Es necesario generar evidencia para el desarrollo de políticas antimicrobianas e intervenciones de administración apropiadas y específicas en la pandemia de COVID-19.

3.
Rev Argent Microbiol ; 54(3): 247-257, 2022.
Article in English | MEDLINE | ID: mdl-35931565

ABSTRACT

Bacterial co-pathogens are commonly identified in viral respiratory infections and are important causes of morbid-mortality. The prevalence of Chlamydia (C.) pneumoniae infection in patients infected with SARS-CoV-2 has not been sufficiently studied. The objective of the present review was to describe the prevalence of C. pneumoniae in patients with coronavirus disease 2019 (COVID-19). A search in MEDLINE and Google Scholar databases for English language literature published between January 2020 and August 2021 was performed. Studies evaluating patients with confirmed COVID-19 and reporting the simultaneous detection of C. pneumoniae were included. Eleven articles were included in the systematic review (5 case cross-sectional studies and 6 retrospective studies). A total of 18450 patients were included in the eleven studies. The detection of laboratory-confirmed C. pneumoniae infection varied between 1.78 and 71.4% of the total number of co-infections. The median age of patients ranged from 35 to 71 years old and 65% were male. Most of the studies reported one or more pre-existing comorbidities and the majority of the patients presented with fever, cough and dyspnea. Lymphopenia and eosinopenia were described in COVID-19 co-infected patients. The main chest CT scan showed a ground glass density shadow, consolidation and bilateral pneumonia. Most patients received empirical antibiotics. Bacterial co-infection was not associated with increased ICU admission and mortality. Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus 2-associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial co-infection. Prospective evidence generation to support the development of an antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic are urgently required.


Subject(s)
Anti-Infective Agents , Bacterial Infections , COVID-19 , Chlamydophila pneumoniae , Coinfection , Adult , Aged , Anti-Bacterial Agents , Bacterial Infections/epidemiology , Coinfection/epidemiology , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Pandemics , Prospective Studies , Retrospective Studies , SARS-CoV-2
4.
Ciudad Autónoma de Buenos Aires; Argentina. Ministerio de Salud de la Nación. Dirección de Investigación en Salud; jul. 2016. 1-13 p. graf.
Non-conventional in Spanish | ARGMSAL, BINACIS | ID: biblio-1400284

ABSTRACT

INTRODUCCIÓN Los métodos moleculares para el diagnóstico de Micoplasma pneumoniae (Mp) son sensibles y más específicos que los serológicos. OBJETIVOS GENERALES Determinar la persistencia de anticuerpos (Ac) IgM y de ADN de Mp en adultos con infección respiratoria aguda (IRA) que requieren internación (casos) y en donantes de sangre. OBJETIVOS ESPECÍFICOS a) Determinar el tiempo que permanecen positivos (+) los Ac IgM anti-Mp por inmunofluorescencia (IF) en casos y donantes. b) Determinar el tiempo que permanece + la detección de ADN de Mp mediante PCR anidada (NPCR) en casos y donantes. c) Analizar las diferencias entre los resultados de ambos grupos. d) Aportar nuevos criterios para la interpretación de los mismos. MÉTODOS Estudio prospectivo, descriptivo y de cohortes que incluyó a >18 años (a) que requerían internación por presentar IRA y donantes de sangre que acudieron entre el 04/16 y 04/17. Los sujetos + por una o dos técnicas se siguieron por un año. Se tomaron muestras respiratorias, sangre y suero. Se utilizaron IF y NPCR. Las diferencias de resultados entre ambos grupos se estimaron mediante la prueba χ². RESULTADOS En 84 casos evaluables se obtuvo 30,9% de IF + y 15,5% de NPCR +. Dos fueron + por ambas pruebas. En 60 donantes se obtuvo 11,6% de IF +, 5% de NPCR +. Uno fue + por ambas pruebas. Las diferencias de resultados + entre casos y donantes fue estadísticamente significativa (p< 0,05). Se siguieron 11 de 37 casos +; 6 tuvieron NPCR + al menos por 2 meses (m) (1 por 10m) y un caso IF + hasta 7m. Se siguieron 6 donantes, 3 fueron IF + por 5m; 2 negativizaron la NPCR a los 2m y uno a los 10m. DISCUSIÓN Se observaron diferencias estadísticamente significativas entre los resultados de casos y donantes. La detección de IgM no permite establecer si la infección es o no reciente (casos + desde 2m a 1 año y hasta 5m en donantes). La NPCR serviría como método confirmatorio de infección reciente, aunque se observó un caso y un donante con persistencia de ADN


Subject(s)
Pneumonia , Serologic Tests , Polymerase Chain Reaction , Diagnosis , Mycoplasma , Mycoplasma pneumoniae
SELECTION OF CITATIONS
SEARCH DETAIL
...